Boston Scientific Corporation

NYSE BSX

Boston Scientific Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD 2.50 B

Boston Scientific Corporation EBIT is USD 2.50 B for the Trailing 12 Months (TTM) ending September 30, 2024, a 16.45% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Boston Scientific Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 2.15 B, a 55.96% change year over year.
  • Boston Scientific Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 1.38 B, a -15.22% change year over year.
  • Boston Scientific Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 1.62 B, a 2,322.39% change year over year.
  • Boston Scientific Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 67.00 M, a -95.02% change year over year.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
Loading...
NYSE: BSX

Boston Scientific Corporation

CEO Mr. Michael F. Mahoney
IPO Date May 19, 1992
Location United States
Headquarters 300 Boston Scientific Way
Employees 48,000
Sector Health Care
Industries
Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Similar companies

DXCM

DexCom, Inc.

USD 79.17

-0.84%

EW

Edwards Lifesciences Corporation

USD 71.04

-0.07%

STE

STERIS plc

USD 207.57

0.10%

SYK

Stryker Corporation

USD 362.80

0.50%

ABT

Abbott Laboratories

USD 113.02

-0.15%

MDT

Medtronic plc

USD 85.25

4.23%

ZBH

Zimmer Biomet Holdings, Inc.

USD 104.71

-0.74%

ZIMV

ZimVie Inc.

USD 13.47

-1.25%

StockViz Staff

January 15, 2025

Any question? Send us an email